Latest news and press releases about Nutriband Inc. (NTRB): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain.
Price
| Price | $7.04 |
| Market Cap | $86M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 16.06 |
| EV / EBITDA | -10.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -109.02% |
| Return on Invested Capital | -126.99% |
| Return on Assets | -110.64% |
| Gross Margin | 33.14% |
| Operating Margin | -435.58% |
| Net Margin | -430.43% |
Related companies: ACET · ACRV · ADAG · CRVO · FBIO · GANX · LITS
Explore sector: Healthcare · Biotechnology
More sections of NTRB: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks